- Viramune® (nevirapine)
- Aptivus® (tipranavir)
Information about the drug products is obtained from public sources or from company representatives and is intended solely for informing community representatives about the options currently available or in development. This information can under no circumstances be intepreted as advertising. The mentioning of any drug products does not mean EECA CAB prioritizes those products or, on the contrary, does not recommend them.
- Non-nucleoside polymerase inhibitors
- BI 207127, twice a day, phase III
- Protease inhibitors
- faldaprevir (BI 201335), once a day, phase III